STOCK TITAN
  1. Home
  2. News
  3. KNW

Know Labs, Inc. - KNW STOCK NEWS

Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.

Know Labs, Inc. (KNW) is a pioneering company in the medical diagnostics sector, dedicated to the development, marketing, and sales of cutting-edge technologies. The company specializes in utilizing electromagnetic energy to identify, authenticate, and analyze various substances and materials through its proprietary Bio-RFID and ChromaID technologies.

The Bio-RFID technology is revolutionizing the industry by enabling non-invasive glucose monitoring, providing a significant advancement for diabetes management. Similarly, the ChromaID technology uses structured light to capture unique spectral patterns known as ChromAIDs, which can be matched against databases to identify and detect markers invisible to the human eye. These technologies offer potential solutions that were previously only possible with large, lab-based tests.

Know Labs is currently focused on the development of a wearable device designed to measure blood glucose levels without the need for fingersticks or microneedles. This innovative product aims to improve the quality of life for individuals with diabetes by providing a painless and convenient method of monitoring blood sugar levels.

The company has recently achieved significant milestones in its research and development efforts, showcasing its commitment to pushing the boundaries of medical diagnostics. Know Labs is also actively engaged in forging strategic partnerships to enhance its technological capabilities and expand its market reach.

Financially, Know Labs continues to invest in research and development, ensuring it remains at the forefront of medical diagnostic innovation. The company's disruptive technologies hold the promise of making advanced diagnostics more accessible and affordable, thereby transforming the landscape of healthcare.

For the latest updates, news, and developments related to Know Labs, Inc., visit our news section or follow us on our social media channels.

News

Know Labs Expands Medical and Scientific Advisory Board

Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) appoints four new members to its Medical and Scientific Advisory Board. Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan, and Dr. Satish Garg bring extensive clinical diabetes management and FDA expertise to the board. They will support the development and FDA clearance of the company's non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
management
-
News

Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023

Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. The company is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences earnings
-
News

Know Labs Expands Board of Directors

Rhea-AI Summary
KNW: Know Labs, Inc. Appoints Three New Directors with Deep Sector Expertise. The company has named John Cronin, Larry Ellingson, and Tim Londergan to its Board of Directors. The new appointees bring extensive sector-relevant experience and deep knowledge of the science and marketplace focused on Know Labs, expanding the board to seven members. John Cronin, the founder and CEO of ipCapital Group, Inc., has played a pivotal role in increasing Know Labs' patent portfolio and global leadership in non-invasive blood glucose monitoring. Larry Ellingson, with 30 years at Eli Lilly, has been instrumental in shaping Know Labs' strategy and global relationships. Tim Londergan, founder and CEO of Tangibly, Inc., brings expertise in trade secret management and enhancing IP portfolios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

Know Labs Presents at Third Annual Bernstein CGM Disruptors Conference, Details Significant Progress During the Past Year

Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will present at the Bernstein CGM Disruptors Conference. The company has seen a 176% increase in patents issued, pending, and in process for non-invasive blood glucose monitoring. They have also published peer-reviewed reports on clinical results and completed production of their Generation 1 working prototype. The CFO will provide updates on the company's diagnostic technology platform and the path to bringing the first FDA-cleared non-invasive blood glucose monitor to the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
News

Know Labs, Inc. Announces Pricing of $7 Million Public Offering of Common Stock

Rhea-AI Summary
Know Labs, Inc. announces pricing of public offering at $0.25 per share, expected to raise $7 million. Proceeds to be used for product development, clinical studies, and other expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.43%
Tags
offering
-
News

Know Labs, Inc. Reports Third Quarter FY2023 Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
earnings
News

Know Labs, Inc. to Host Review of Third Quarter Fiscal Year 2023 Results on August 14, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

Know Labs Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Rhea-AI Summary
KNW - Know Labs, Inc. announced results from a new study demonstrating the improved accuracy of its proprietary Bio-RFID sensor technology for non-invasive blood glucose monitoring. The study validated algorithm performance and data preprocessing techniques, achieving an overall Mean Absolute Relative Difference (MARD) of 11.3%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
News

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
News

Know Labs’ Non-Invasive Glucose Monitoring Technology Shows Improved Accuracy

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none

FAQ

What is the current stock price of Know Labs (KNW)?

The current stock price of Know Labs (KNW) is $0.1339 as of January 21, 2025.

What is the market cap of Know Labs (KNW)?

The market cap of Know Labs (KNW) is approximately 15.3M.

What does Know Labs, Inc. specialize in?

Know Labs, Inc. specializes in the development, marketing, and sales of technologies that use electromagnetic energy to identify and authenticate substances and materials.

What is Bio-RFID technology?

Bio-RFID technology is a non-invasive method developed by Know Labs to measure blood glucose levels without fingersticks or microneedles.

What is ChromaID technology?

ChromaID technology uses structured light to capture unique spectral patterns, known as ChromAIDs, which can identify and detect markers invisible to the human eye.

What is the latest product being developed by Know Labs?

Know Labs is currently developing a wearable device that measures blood glucose levels non-invasively.

What are ChromAIDs?

ChromAIDs are unique spectral patterns captured by ChromaID technology, used to identify and detect various markers.

How does Know Labs' technology differ from traditional diagnostic methods?

Know Labs' technologies offer non-invasive, portable, and cost-effective diagnostic solutions that were traditionally only possible with large, lab-based equipment.

What are the recent achievements of Know Labs?

Know Labs has achieved significant milestones in research and development, advancing its Bio-RFID and ChromaID technologies and working on a non-invasive glucose monitoring device.

How does Know Labs contribute to diabetes management?

Know Labs is developing a wearable device for non-invasive glucose monitoring, which aims to provide a painless and convenient method for individuals to manage their blood sugar levels.

Who can benefit from Know Labs' technologies?

Individuals with diabetes, medical professionals, and various industries requiring substance identification and authentication can benefit from Know Labs' innovative technologies.

Where can I find the latest news about Know Labs, Inc.?

You can find the latest updates and news about Know Labs, Inc. on their news section on their website or follow them on social media channels.
Stock KNW logo
Know Labs, Inc.

NYSE:KNW

KNW Rankings

#5490 Ranked by Market Cap
N/A Ranked by Dividends

KNW Stock Data

15.29M
88.76M
26.05%
4.83%
1.2%
Scientific & Technical Instruments
Measuring & Controlling Devices, Nec
Link
United States of America
SEATTLE